ABSTRACT

Background: Prostate cancer (PC) is the second most common type of cancer in men worldwide and the fifth most common cancer among Korean men. Although most PCs grow slowly, it is unclear whether a longer time interval from diagnosis to treatment causes worse outcomes. This study aimed to investigate whether the time interval from diagnosis to radical prostatectomy (RP) in men with clinically localized PC affects postoperative oncologic outcomes.

Methods: We retrospectively analyzed data of 427 men who underwent RP for localized PC between January 2005 and June 2016. The patients were divided into two groups based on the cutoff median time interval (100 days) from biopsy to surgery. The associations between time interval from biopsy to surgery (< 100 vs. ≥ 100 days) and adverse pathologic outcomes such as positive surgical margin, pathologic upgrading, and upstaging were evaluated. Biochemical recurrence (BCR)-free survival rates were analyzed and compared based on the time interval from biopsy to surgery.

Results: Pathologic upgrading of Gleason score in surgical specimens was more frequent in the longer time interval group and showed marginal significance (38.8% vs. 30.0%; \( P = 0.057 \)). Based on multivariable analysis, an association was observed between time interval from biopsy to surgery (≤ 100 vs. ≥ 100 days) and adverse pathologic outcomes such as positive surgical margin, pathologic upgrading, and upstaging were evaluated. Biochemical recurrence (BCR)-free survival rates were analyzed and compared based on the time interval from biopsy to surgery.

Conclusion: Time interval ≥ 100 days from biopsy to RP in clinically localized PC increased the risk of pathologic upgrading but did not affect long-term BCR-free survival rates in Korean men.

Keywords: Prostate; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome

INTRODUCTION

Due to the increased use of prostate-specific antigen (PSA) testing and prostate cancer (PC) screening programs, the diagnosis rate of early-stage PC has increased.\(^1\,^2\) Men diagnosed with localized PC have several treatment options, including radical prostatectomy (RP),...
Disclosure
The authors have no potential conflicts of interest to disclose.

Author Contributions
Conceptualization: Kim YB. Data curation: Kim SJ. Formal analysis: Kim SJ, Ryu JH. Methodology: Yang SO, Lee JK. Validation: Jung TY. Writing - original draft: Kim SJ. Writing - review & editing: Ryu JH, Jung TY, Kim YB.

radiation therapy, and active surveillance. Minimally invasive treatments such as focal cryotherapy have emerged and show encouraging outcomes.

Among the several treatment options, optimum treatment of clinically localized PC remains controversial, and determining the best treatment strategy is difficult for both doctors and patients. Recently, most patients have preferred to play an active role in the treatment decision-making process, and almost all patients reported satisfaction with their decision. This decision-making process may take a fairly long time; and several factors may affect the time interval between biopsy and surgery.

Post-biopsy changes on magnetic resonance imaging (MRI) for staging workup can last up to 21 days and in some cases up to 4.5 months after prostate biopsy. Although multiparametric MRI can help distinguish between PC and hemorrhage due to biopsy, delaying MRI for several weeks after biopsy to allow for hemorrhage absorption may improve the accuracy of staging work-up. When planning surgery, the currently widely accepted practice is to wait at least 6 weeks after a prostate biopsy before undergoing RP for PC because waiting a short time before RP could produce periprostatic inflammatory adhesions or hematomas resulting from biopsy. Other factors such as clinician or institution schedules may cause an additional delay to surgery.

As the decision-making process and the time interval to surgery become longer, there is a concern that postoperative outcome may be poor due to the longer time interval, although PC shows slow progression. Actually, pathologic Gleason score (GS) upgrading has been found in 30% to 50% of RP specimens, indicating that tumor grade increases between biopsy and surgery.

Many reports have been published on whether a longer time interval from biopsy to surgery for clinically localized PC has adverse effects on postoperative outcome; however, the results are controversial, and studies on Korean men have not been reported.

In this retrospective study, we investigated whether a longer time interval between prostate biopsy and RP is associated with poor postoperative outcome in Korean men with localized PC. We compared adverse pathologic outcomes based on multiple variables and biochemical recurrence (BCR) based on time interval from biopsy to RP.

METHODS

Patient population and inclusion criteria
Data of 603 men who underwent open RP for clinically localized PC between January 2005 and June 2016 were retrospectively analyzed in this institutional review board (IRB)-approved study. Surgery was performed by five urologists using the retropubic approach. Patients who had previously undergone prostate surgery such as transurethral resection of prostate and photovaporization of prostate (n = 4) or preoperative adjuvant radiation or hormonal therapy (n = 16) were excluded. Patients with incomplete preoperative data (n = 20) or lack of follow-up within 12 months (n = 24) were also excluded. Among these patients, data of very low-, low-, and intermediate-risk patients according to the National Comprehensive Cancer Network (NCCN) guidelines, which are considered for localized PC, were extracted; finally,
427 patients were included in the analysis. No included patient had signs of lymph node or distant metastasis on preoperative imaging or final surgical pathology.

PC risk classification according to the 2018 NCCN guidelines is as follows: low-risk is defined as biopsy GS sum ≤ 6, PSA < 10 ng/mL, and clinical stage ≤ T2a; intermediate-risk is defined as biopsy GS sum 7, PSA 10–20 ng/mL, and clinical stage T2b–T2c. Very-low risk (clinical stage T1c, GS sum ≤ 6, PSA < 10 ng/mL, fewer than 3 positive prostate biopsy fragments/cores, ≤ 50% cancer in each fragment/core, and PSA density < 0.15 ng/mL/g) patients were included in the low-risk group due to the small number of patients (n = 9) and for simplicity of group distribution.

Postoperative follow-up included measurement of the serum PSA level and physical examinations at 2- to 3-month intervals for the first year after surgery, 6-month intervals for the second year, and annually thereafter. BCR was defined as two consecutive PSA results > 0.2 ng/mL, and the first elevated time point was defined as the BCR point.

Because the median time interval was 100 days, the patients were stratified into two groups based on the time interval from biopsy to RP, < 100 days and ≥ 100 days. Prostate volume was calculated by multiplying height, width, and length measured on transrectal ultrasonography or MRI of prostate and \( \pi/6 \).

**Statistical analysis**

Univariable analysis of preoperative and pathologic characteristics was performed based on the time interval from biopsy to RP using Pearson’s \( \chi^2 \) test for categorical variables and Student's \( t \)-test for continuous variables.

Adverse pathologic events such as positive surgical margin (PSM), pathologic upgrading, and upstaging were analyzed based on the time interval from biopsy to RP. Only very low-, low-, and intermediate-risk patients were analyzed; all patients had GS sum ≤ 7 and clinical stage ≤ T2. Pathologic upgrading was defined as a GS sum of RP specimen ≥ 7 when biopsy GS sum was ≤ 6 or GS sum of RP specimen greater than the biopsy GS sum when biopsy GS sum was 7. Pathologic upstaging was defined as a pathologic RP specimen stage ≥ T3.

The associations between time interval from biopsy to RP and adverse pathologic events in the RP specimen were evaluated with univariable analysis using \( \chi^2 \) tests and multivariable logistic regression analysis for each adverse event.

BCR-free survival rates in each group were analyzed using the Kaplan-Meier method and compared with the log-rank test. A Cox proportional hazards model was used after adjusting for preoperative features to estimate the hazard ratio (HR) and 95% confidence interval (CI) of BCR associated with the time interval from biopsy to RP. All statistical analyses were performed using IBM SPSS 18.0 (IBM Co., Armonk, NY, USA), and a \( P \) value < 0.05 was considered statistically significant.

**Ethics statement**

The study protocol was approved by the Institutional Review Board (IRB) of Veterans Health Service Medical Center (approval No. 2017-04-001-004). Informed consent was waived by the IRB.
RESULTS

Preoperative parameters and pathologic outcomes

The preoperative and pathologic characteristics of patients are shown in Table 1. Because the median time from biopsy to RP was 100 days, the patients were classified into two groups based on this cutoff. Among the 427 men, 213 (50%) were treated < 100 days after biopsy (shorter time interval group) and 214 patients (50%) were treated > 100 days after biopsy.

Table 1. Preoperative and pathologic characteristics of all patients, low-risk patients, and intermediate-risk patients

| Variables | < 100 days (n = 213) | ≥ 100 days (n = 214) | P value |
|-----------|----------------------|----------------------|---------|
| All patients | | | |
| Age, yr | 68.46 ± 5.407 | 67.76 ± 3.920 | 0.127 |
| PSA, ng/mL | 7.702 ± 3.696 | 6.666 ± 2.741 | 0.001 |
| Prostate volume, mL | 35.956 ± 14.644 | 37.403 ± 13.779 | 0.293 |
| PSA density, ng/mL/mL | 0.240 ± 0.149 | 0.194 ± 0.956 | 0.000 |
| Positive cores, % | 29.393 ± 19.842 | 25.520 ± 20.537 | 0.048 |
| Time interval to RP, day | 75.535 ± 16.211 | 147.168 ± 77.78 | < 0.001 |
| Follow-up, day | 2,486.070 ± 996.423 | 1,588.02 ± 831.91 | < 0.001 |
| Biopsy GS, No. (%) | | | 0.250 |
| ≤ 6 | 125 (58.7) | 117 (54.7) | |
| 7 (3 + 4) | 67 (31.5) | 82 (38.3) | |
| 7 (4 + 3) | 21 (9.9) | 15 (7) | |
| Clinical stage, No. (%) | | < 0.001 |
| ≤ T2a | 119 (55.9) | 157 (73.4) | |
| T2b–T2c | 94 (44.1) | 57 (26.6) | |
| RP GS, No. (%) | | 0.152 |
| ≤ 6 | 76 (35.7) | 55 (25.7) | |
| 7 (3 + 4) | 101 (47.4) | 117 (54.7) | |
| 7 (4 + 3) | 30 (14.1) | 33 (15.4) | |
| ≥ 8 | 6 (2.8) | 9 (4.2) | |
| Pathologic T stage, No. (%) | | 0.031 |
| T2a | 48 (22.5) | 33 (15.4) | |
| T2b–T2c | 112 (52.6) | 139 (65.0) | |
| T3–T4 | 53 (24.9) | 42 (19.6) | |
| Pathologic N stage, No. (%) | | 0.115 |
| N0 | 28 (13.3) | 18 (8.4) | |
| N1 | 0 (0) | 0 (0) | |
| Nx | 185 (86.9) | 196 (91.6) | |

Low-risk patients | | |
| Age, yr | 68.26 ± 4.555 | 66.54 ± 3.883 | 0.018 |
| PSA, ng/mL | 6.00 ± 2.354 | 5.67 ± 1.569 | 0.331 |
| Prostate volume, mL | 38.835 ± 17.761 | 39.078 ± 13.914 | 0.927 |
| PSA density, ng/mL/mL | 0.176 ± 0.099 | 0.016 ± 0.070 | 0.320 |
| Positive cores, % | 16.833 ± 13.292 | 17.540 ± 16.149 | 0.778 |
| Time interval to RP, day | 76.181 ± 15.770 | 139.184 ± 39.233 | < 0.001 |
| Follow-up, day | 2,347.62 ± 842.535 | 1,761 ± 862.031 | < 0.001 |
| RP GS, No. (%) | | 0.137 |
| ≤ 6 | 37 (56.1) | 28 (36.8) | |
| 7 (3 + 4) | 22 (33.3) | 38 (50.0) | |
| 7 (4 + 3) | 5 (7.6) | 8 (10.5) | |
| ≥ 8 | 2 (3) | 2 (2.6) | |
| Pathologic T stage, No. (%) | | 0.079 |
| T2a | 24 (36.4) | 15 (19.7) | |
| T2b–T2c | 36 (54.3) | 54 (71.1) | |
| T3–T4 | 6 (9.3) | 7 (9.2) | |
| Pathologic N stage, No. (%) | | |
| Nx | 66 (100) | 76 (100) | |

(continued to the next page)
Subgroup classification according to NCCN guidelines revealed 142 (33.3%) low-risk patients and 285 (66.7%) intermediate-risk patients. Men in the longer time interval group showed statistically significantly lower PSA level, lower PSA density, shorter follow-up duration, lower clinical stage, and lower pathologic T stage. Based on subgroup analysis, follow-up duration was significantly shorter in the longer time interval group for both low- and intermediate-risk groups. PSA level, PSA density, and clinical stage were significantly lower in the longer time interval group.

Univariable analysis results of adverse pathologic events are presented in Table 2. Statistical difference in adverse pathologic events was not observed based on time interval. However, pathologic upgrading was higher in the longer time interval group though the difference was not significant (38.8% vs. 30.0%; \( P = 0.057 \)). In the subgroup analysis, a longer time interval from biopsy to RP was significantly associated with pathologic upgrading only in the low-risk group (\( P = 0.022 \)).

Based on multivariable logistic regression analysis, a longer time interval was significantly associated with pathologic upgrading (odds ratio [OR], 2.211; 95% CI, 1.342–3.645; \( P = 0.002 \)) but not with PSM or pathologic upstaging (Table 3). PSA (OR, 1.110; 95% CI, 1.042–1.183; \( P = 0.001 \)) and prostate volume (OR, 0.971; 95% CI, 0.955–0.988; \( P = 0.001 \)) were associated with PSM. PSA (OR, 1.180; 95% CI, 1.096–1.270; \( P < 0.001 \)), prostate volume (OR, 0.953; 95% CI, 0.931–0.976; \( P < 0.001 \)), and preoperative biopsy GS (OR, 2.520; 95% CI, 1.515–4.190; \( P < 0.001 \)) were associated with pathologic upstaging.
Based on multivariable subgroup analysis, significant association was observed between the time interval from biopsy to RP and pathologic upgrading in the low-risk group (OR, 2.420; 95% CI, 1.188–4.931; \( P = 0.015 \)), and a longer time interval tended to increase the risk of pathologic upgrading in the intermediate-risk group (OR, 2.006; 95% CI, 0.982–4.096; \( P = 0.056 \)).

**Long-term BCR-free survival**

Fig. 1 shows the Kaplan-Meier curves for BCR-free survival in all patients, and Fig. 2 shows the results for each PC risk group. Significant differences were not observed in BCR-free survival based on the time interval from biopsy to RP.

### Table 2. Adverse pathologic events in all patients, low-risk patients, and intermediate-risk patients

| Variables | < 100 days (n = 213) | ≥ 100 days (n = 214) | \( P \) value |
|-----------|----------------------|----------------------|--------------|

#### All patients

| PSM | 81 (38.0) | 87 (40.7) | 0.579 |
| Upgrading | 66 (30.0) | 83 (38.8) | 0.057 |
| Upstaging | 53 (24.9) | 42 (19.6) | 0.192 |

#### Low-risk patients

| PSM | < 100 days (n = 66) | ≥ 100 days (n = 76) | \( P \) value |
| Upgrading | 16 (24.2) | 27 (35.5) | 0.344 |
| Upstaging | 29 (43.9) | 48 (61.2) | 0.022 |

#### Intermediate-risk patients

| PSM | < 100 days (n = 147) | ≥ 100 days (n = 138) | \( P \) value |
| Upgrading | 65 (44.2) | 60 (43.5) | 0.900 |
| Upstaging | 35 (23.8) | 35 (25.4) | 0.761 |

Data are presented as number (%).

PSM = positive surgical margin

### Table 3. Multivariable analysis of adverse pathologic events in all patients, low-risk patients, and intermediate-risk patients

| Variables | PSM | \( OR \) (95% CI) | \( P \) value | Upgrading | \( OR \) (95% CI) | \( P \) value | Upstaging | \( OR \) (95% CI) | \( P \) value |
|-----------|-----|------------------|--------------|-----------|------------------|--------------|-----------|------------------|--------------|

#### All patients (n = 427)

| Age | 1.010 (0.967–1.055) | 0.667 | 1.023 (0.971–1.078) | 0.388 | 1.039 (0.985–1.095) | 0.158 |
| PSA | 1.110 (1.042–1.183) | 0.001 | 1.056 (0.978–1.140) | 0.163 | 1.180 (1.096–1.270) | < 0.001 |
| Prostate volume | 0.971 (0.955–0.988) | 0.001 | 0.978 (0.961–0.996) | 0.015 | 0.953 (0.931–0.976) | < 0.001 |
| Biopsy GS 7 vs. ≤ 6 | 1.155 (0.764–1.749) | 0.494 | 0.037 (0.019–0.075) | < 0.001 | 2.520 (1.515–4.190) | < 0.001 |
| Clinical stage T2b–T2c vs. ≤ T2a | 1.472 (0.958–2.261) | 0.078 | 1.139 (0.673–1.928) | 0.629 | 1.463 (0.872–2.455) | 0.149 |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.412 (0.929–2.147) | 0.106 | 2.211 (1.342–3.645) | 0.002 | 1.014 (0.604–1.702) | 0.959 |

#### Low-risk patients (n = 142)

| Age | 0.994 (0.906–1.091) | 0.903 | 1.024 (0.942–1.133) | 0.576 | 1.028 (0.894–1.183) | 0.695 |
| PSA | 1.179 (0.958–1.451) | 0.120 | 1.024 (0.859–1.221) | 0.788 | 1.089 (0.850–1.395) | 0.501 |
| Prostate volume | 0.950 (0.919–0.982) | 0.003 | 0.970 (0.946–0.995) | 0.018 | 0.956 (0.908–1.008) | 0.094 |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.990 (0.902–4.387) | 0.088 | 2.420 (1.188–4.931) | 0.015 | 1.167 (0.351–3.873) | 0.801 |

#### Intermediate-risk patients (n = 285)

| Age | 1.013 (0.964–1.065) | 0.608 | 1.020 (0.953–1.091) | 0.571 | 1.039 (0.981–1.101) | 0.190 |
| PSA | 1.094 (1.018–1.175) | 0.014 | 1.059 (0.959–1.170) | 0.257 | 1.181 (1.088–1.283) | < 0.001 |
| Prostate volume | 0.980 (0.961–1.000) | 0.046 | 0.988 (0.962–1.015) | 0.395 | 0.952 (0.927–0.978) | < 0.001 |
| Biopsy GS 7 vs. ≤ 6 | 1.155 (0.665–2.006) | 0.608 | 0.041 (0.018–0.094) | < 0.001 | 2.296 (1.192–4.425) | 0.013 |
| Clinical stage T2b–T2c vs. ≤ T2a | 1.432 (0.840–2.440) | 0.187 | 1.173 (0.514–2.675) | 0.704 | 1.350 (0.744–2.448) | 0.324 |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.203 (0.729–1.987) | 0.469 | 2.006 (0.982–4.096) | 0.056 | 0.962 (0.539–1.718) | 0.897 |

PSM = positive surgical margin, OR = odds ratio, CI = confidence interval, PSA = prostate-specific antigen, GS = Gleason score, RP = radical prostatectomy.
Based on multivariable Cox proportional hazard analysis, PSA level (HR, 1.073; 95% CI, 1.013–1.137; \(P = 0.017\)) and prostate volume (HR, 0.960; 95% CI, 0.939–0.982; \(P < 0.001\)) were significantly associated with BCR; however, a longer time interval was not associated with BCR (HR, 1.285; 95% CI, 0.795–2.077; \(P = 0.305\)) (Table 4). When subgroup analysis was performed, increased risk of BCR was not observed with a longer time interval in either group.

![Kaplan-Meier BCR-free survival of all patients](https://jkms.org)

**Fig. 1.** Kaplan–Meier BCR-free survival of all patients (log-rank test, \(P = 0.988\)).

**Table 4.** Multivariable analysis of BCR for all patients, low-risk patients, and intermediate-risk patients

| Variables                        | HR (95% CI)         | \(P\) value |
|----------------------------------|---------------------|-------------|
| **All patients (n = 427)**       |                     |             |
| Age                              | 1.042 (0.993–1.094) | 0.094       |
| PSA                              | 1.073 (1.013–1.137) | 0.017       |
| Prostate volume                  | 0.960 (0.939–0.982) | < 0.001     |
| Biopsy GS 7 vs. ≤ 6              | 1.481 (0.935–2.347) | 0.094       |
| Clinical stage                   |                     |             |
| T2b–T2c vs. ≤ T2a                | 1.207 (0.753–1.933) | 0.435       |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.285 (0.795–2.077) | 0.305       |
| **Low-risk patients (n = 142)**  |                     |             |
| Age                              | 1.157 (1.020–1.313) | 0.023       |
| PSA                              | 0.977 (0.725–1.377) | 0.879       |
| Prostate volume                  | 0.966 (0.926–1.007) | 0.104       |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.799 (0.653–4.957) | 0.256       |
| **Intermediate-risk patients (n = 285)** |                 |             |
| Age                              | 1.020 (0.967–1.076) | 0.468       |
| PSA                              | 1.079 (1.014–1.148) | 0.017       |
| Prostate volume                  | 0.959 (0.934–0.985) | 0.002       |
| Biopsy GS 7 vs. ≤ 6              | 1.432 (0.794–2.581) | 0.232       |
| Clinical stage                   |                     |             |
| T2b–T2c vs. ≤ T2a                | 1.133 (0.658–1.950) | 0.653       |
| Time interval to RP, day ≥ 100 vs. < 100 | 1.194 (0.687–2.076) | 0.529       |

BCR = biochemical recurrence, HR = hazard ratio, CI = confidence interval, PSA = prostate-specific antigen, GS = Gleason score, RP = radical prostatectomy.
DISCUSSION

Generally, clinically localized PC is considered relatively slow in progression, and a certain time interval to treatment may not have a negative effect on long-term survival. Although many reports have been published on whether the delay of definite treatment is safe, the results are inconclusive.

Khan et al.\textsuperscript{15} analyzed data of 926 men who underwent RP performed by a single urologist. The authors reported that delays of up to several months did not influence long-term BCR rates. Joseph et al.\textsuperscript{17} analyzed 393 men with localized PC who were treated with radiation therapy or surgery. The authors reported that a delay in treatment ≥ 3 months did not appear to adversely affect BCR-free survival in patients who underwent definite therapy for clinically localized PC with low-risk features. In a recent study in the United States, although nearly 50% of men with low-risk PC experienced at least one adverse pathologic outcome at RP, delay of RP for up to 12 months did not change the risk of adverse pathology.\textsuperscript{18} Similar research in Sweden showed no difference between primary and deferred RP performed a median of 2.6 years after diagnosis in frequency of GS ≥ 6, extraprostatic extension, PSM, tumor volume on RP specimens, or BCR rats after a mean follow-up of 5.7 years.\textsuperscript{20}

Conversely, negative results due to surgical delay in RP were reported in several studies. Nam et al.\textsuperscript{21} demonstrated that patients who underwent RP within 3 months of diagnosis experienced significantly higher 10-year BCR-free survival than those who underwent surgery ≥ 3 months after diagnosis (74.6% vs. 61.3%; \( P = 0.05 \)). In addition, O’Brien et al.\textsuperscript{22} reported that a delay of RP > 6 months was associated with pathologic upgrading and BCR in D’Amico low-risk patients. In a recent study in Turkey, Eroglu et al.\textsuperscript{23} suggested that time interval from biopsy to RP is an important factor of pathologic upgrading in clinically T1c PC patients. The authors reported that the mean time to surgery was longer in the pathologic upgrading group (pathologic upgrading group, 52.2 ± 22.6 days; no pathologic upgrading group, 45.3 ± 15.5 days; \( P = 0.004 \)).

**Fig. 2.** Kaplan-Meier BCR-free survival by subgroup according to risk classification. (A) Kaplan-Meier BCR-free survival of low-risk patients (log-rank test, \( P = 0.549 \)). (B) Kaplan-Meier BCR-free survival of intermediate-risk patients (log-rank test, \( P = 0.859 \)). BCR = biochemical recurrence.
The above-mentioned studies were conducted on Western men; studies on Asian men have not been performed. Reportedly, in several epidemiologic studies, PC aggressiveness was associated with racial and ethnic differences, and advanced-stage and high-grade PC presented more frequently in Asian than in Caucasian men.\textsuperscript{24-26} Although, with the introduction of PSA screening in Korea, a GS 6 has become the most dominant histologic grade at diagnosis,\textsuperscript{27} the incidence of high-grade or advanced stage PC was higher in Korean men who had undergone RP than in Western men in several studies.\textsuperscript{28,29}

In the present study, the data of patients who underwent RP at our institution were retrospectively analyzed based on time interval from biopsy to RP and PC risk. Whether the time interval from biopsy to RP influences the pathologic outcomes and long-term BCR was investigated. To the best of our knowledge, whether the time interval from prostate biopsy to RP influences postoperative outcomes in Asian men was investigated for the first time in this study. Results showed that time interval from biopsy to RP > 100 days was associated with pathologic upgrading but did not affect BCR-free survival.

Pathologic GS upgrading has been found in 30% to 50% of RP specimens,\textsuperscript{13,14} indicating either incorrect biopsy GS or worsened tumor grade between biopsy and surgery. In the present study, the pathologic upgrading rate was 34.4%, which was similar to the results in previous studies.

Based on multivariable analysis of time interval from biopsy to surgery, > 100 days significantly increased the risk of pathologic upgrading but not long-term BCR rates. We hypothesized that longer time interval from biopsy to surgery resulted in worsening of tumor grade and higher risk of pathologic upgrading. However, because time interval from biopsy to surgery did not affect other pathologic outcomes such as pathologic upstaging or PSM rate, pathologic upgrading alone did not appear to adversely affect long-term BCR rates.

The present study had several limitations. This was a retrospective study and was thus inherently limited. Because patients were treated by five different urologists, the surgical techniques and follow-up schedule may have differed slightly. However, all of the surgeons were expert urologists, and the follow-up schedule did not differ significantly. Next, the study cohort was not sufficiently large to fully ascertain the risk of delay in each risk group. Next, the follow-up period was significantly different between the two groups classified based on time interval from biopsy to RP, potentially because surgical delay was more common in recent years. However, several investigators demonstrated that the majority of BCR after RP occurs in the first few years; therefore, the impact of the time interval from biopsy to RP on BCR was likely not affected by differences in the follow-up period.\textsuperscript{30} Finally, patient stress when experiencing a relatively long interval time to surgery would not be low. The impacts of stress and anxiety were not investigated in this study, but this is a matter that medical staff should consider and that warrants future research.

In conclusion, an interval of ≥ 100 days from biopsy to surgery was associated with pathologic upgrading but did not affect long-term BCR-free survival rates in Korean men. Although this is a retrospective study, these findings may be used to allay patient anxiety when either patient or institutional factors result in a reasonably long time interval from biopsy to RP in localized PC. However, the precise relationship between interval from biopsy to RP and patient outcomes remains unclear, and shorter interval from biopsy to RP may prevent worsening in pathologic grade. If prospective randomized studies are performed including
cancer-specific and overall mortality rates, the effect of longer interval from biopsy to RP will be more apparent.

REFERENCES

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. *JAMA* 1993;270(8):948-54. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/8433723/) | [CROSSREF](https://doi.org/10.1001/jama.1993.03500080065031)

2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. *J Urol* 2007;178(3 Pt 2):514-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17668518/) | [CROSSREF](https://doi.org/10.1016/j.juro.2007.03.025)

3. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. *J Urol* 2007;177(6):2106-31. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17489371/) | [CROSSREF](https://doi.org/10.1016/j.juro.2007.03.025)

4. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. *J Natl Compr Canc Netw* 2016;14(1):19-30. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27398093/) | [CROSSREF](https://doi.org/10.6004/jnccn.2016.0065)

5. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. *Eur Urol* 2012;62(1):55-63. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/22300813/) | [CROSSREF](https://doi.org/10.1016/j.eururo.2012.01.024)

6. Hurwitz LM, Cullen J, Elsamanoudi S, Kim DJ, Hudak J, Colston M, et al. A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic. *Urol Oncol* 2016;34(5):233.e17-233.e25. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27193908/) | [CROSSREF](https://doi.org/10.1016/j.urolonc.2016.01.011)

7. White S, Hricak H, Forstner R, Kurhanewicz J, Sokoloff DL, Nelson SJ, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. *Radiology* 1998;206(3):785-90. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/9715020/) | [CROSSREF](https://doi.org/10.1148/radiology.206.3.9715020)

8. Chun FK, Steuber T, Ebbersdohler A, Curtlin E, Walz J, Schloemann et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. *Eur Urol* 2006;49(5):820-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/16677796/) | [CROSSREF](https://doi.org/10.1016/j.eururo.2005.12.023)

9. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. *J Urol* 2004;172(5 Pt 1):1835-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15374624/) | [CROSSREF](https://doi.org/10.1016/j.juro.2004.03.098)

10. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, et al. Delayed RP for intermediate-risk Pca is associated with BCR: Possible implications for AS from the SEARCH database. *Prostate* 2013;73(4):409-17. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/23506406/) | [CROSSREF](https://doi.org/10.1002/pros.22356)

11. Schaeffer EM, Partin AW, Lepor H. Open radical prostatectomy. In: Wein A, Kavoussi L, Partin A, Peters C, editors. *Campbell-Walsh Urology*. 11th ed. Philadelphia, PA: Elsevier Inc.; 2015, 2641-63.

12. Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. *Acta Radiol* 2001;42(1):70-3.

13. Fukuji T, Namiki T, Namiki H, Carlile RG, Shimada M, Yoshida H. Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens. *Pathol Int* 2001;51(5):364-70. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/11335083/) | [CROSSREF](https://doi.org/10.1080/08035470190013970)

14. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. *J Urol* 2004;172(5 Pt 1):1835-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15374624/) | [CROSSREF](https://doi.org/10.1016/j.juro.2004.03.098)
17. Phillips JJ, Hall MC, Lee WR, Clark PE. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? *Urol Oncol* 2007;25(3):196-200.  
**PUBMED** | **CROSSREF**

18. Weiner AB, Patel SG, Eggener SE. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. *Urol Oncol* 2015;33(4):164.e11-164.e17.  
**PUBMED** | **CROSSREF**

19. Shibata A, Mohanasundaram UM, Terris MK. Interval from prostate biopsy to RP-effect on PSA, GS and risk of recurrence. *Urology* 2005;66(4):808-13.  
**PUBMED** | **CROSSREF**

20. van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? *Cancer* 2010;116(5):1281-90.  
**PUBMED** | **CROSSREF**

21. Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsilias J, Toi A, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. *Can J Urol* 2003;10(3):1891-8.  
**PUBMED**

22. O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, et al. Delay of surgery in men with low risk prostate cancer. *J Urol* 2011;185(6):2143-7.  
**PUBMED** | **CROSSREF**

23. Eroglu M, Doluoglu OG, Sarici H, Telli O, Ozgur BC, Bozkurt S. Does the time from biopsy to radical prostatectomy affect Gleason score upgrading in patients with clinical t1c prostate cancer? *Korean J Urol* 2014;55(6):395-9.  
**PUBMED** | **CROSSREF**

24. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995–2004. *Cancer* 2007;110(6):1255-63.  
**PUBMED** | **CROSSREF**

25. Man A, Pickles T, Chi KNG British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. *J Urol* 2003;170(3):901-4.  
**PUBMED** | **CROSSREF**

26. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. *J Natl Cancer Inst* 2013;105(14):1050-8.  
**PUBMED** | **CROSSREF**

27. Kang DI, Chung HJ, Ha HK, Min K, Yoon J, Kim W, et al. Korean prostate cancer patients have worse disease characteristics than their American counterparts. *Asian Pac J Cancer Prev* 2013;14(11):6913-7.  
**PUBMED** | **CROSSREF**

28. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. *J Urol* 2002;167(2 Pt 1):528-34.  
**PUBMED** | **CROSSREF**